April Issue Must-Read!
Hidradenitis suppurativa (HS) isn’t just painful—it’s deeply isolating. And new data reveals why: the majority of people living with HS don’t feel heard, treated, or informed.
In a survey of over 500 respondents, less than 20% reported satisfaction with current treatments. Even among those with moderate to severe disease, many weren’t receiving biologics or hormone therapy—treatments recommended in current guidelines. Even more surprising? Three-quarters had no idea FDA-approved therapies for HS even existed, and more than half said their doctors never mentioned them.
This eye-opening disconnect points to more than just a therapeutic gap—it’s a communication crisis. But there’s a silver lining: most respondents believed access to FDA-approved treatments could improve their physical health, mental well-being, and relationships.
The message is clear—empowering patients through better provider education and clearer communication may be just as powerful as the treatment itself.
J Drugs Dermatol. 2025;24(4):381-385. doi:10.36849/JDD.8867
